Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A compound pharmaceutical composition for coronary heart disease

A composition and technology for coronary heart disease, applied in the direction of drug combinations, cardiovascular system diseases, active ingredients of heterocyclic compounds, etc., can solve the problem that there are no literature reports on the combined application of atorvastatin calcium and atraleuton, and no literature reports The compound pharmaceutical composition and atrileutone have little anti-inflammatory effect, so as to prevent and treat thrombosis and complications, reduce high-sensitivity C-reactive protein and plasma interleukin, and have a good protective effect

Active Publication Date: 2022-07-01
THE FIFTH PEOPLES HOSPITAL OF SHANGHAI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current research reports show that atraleutone has a small anti-inflammatory effect, and the improvement effect on inflammation is not obvious, and there is a lack of sufficient large-scale, multi-center clinical research results to confirm the therapeutic value of atraleutone
[0005] At present, there is no document reporting the combined application of atorvastatin calcium and atraleutone, nor is there any document reporting the compound pharmaceutical composition of atorvastatin calcium and atraleutone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound pharmaceutical composition for coronary heart disease
  • A compound pharmaceutical composition for coronary heart disease
  • A compound pharmaceutical composition for coronary heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] prescription:

[0078]

[0079]

[0080] Preparation process: Weigh atorvastatin calcium, atraliuton, lactose, sodium carboxymethyl starch, and hypromellose and mix them evenly, add water and mix to make soft materials, pass through a 20-mesh sieve to make wet granules, and dry at 60°C , 20-mesh sieve to granulate, add magnesium stearate, mix well, press into tablets, and get it.

Embodiment 2

[0082] prescription:

[0083]

[0084] Preparation process: Weigh atorvastatin calcium, atraliuton, lactose, microcrystalline cellulose, low-substituted hydroxypropyl fiber, and hypromellose and mix them evenly, add water and mix to make soft materials, pass through a 20-mesh sieve to make Wet granules, dried at 60°C, sized with a 20-mesh sieve, added with magnesium stearate, mixed evenly, and pressed into tablets.

Embodiment 3

[0086] prescription:

[0087]

[0088]

[0089] Preparation process: Weigh atorvastatin calcium, atraliuton, lactose, starch, sodium carboxymethyl cellulose, hypromellose and mix them evenly, add water and mix to make soft materials, pass through a 20-mesh sieve to make wet granules, Dry at 60°C, sieve with a 20-mesh sieve, add talc, mix well, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of atorvastatin calcium and atraliuton in the preparation of medicine for treating and preventing coronary heart disease, and a compound medicine composition for treating coronary heart disease. Inhibition of high-sensitivity C-reactive protein and plasma interleukin, etc., and can stabilize the size of coronary plaque, and even have the effect of reversing plaque, and can effectively prevent and treat atherosclerotic plaque by inhibiting inflammation Thrombosis and the formation of complications in the block have a good protective effect on the cardiovascular system.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, in particular to the use of combined administration of atorvastatin calcium and atraruton for treating coronary heart disease and a compound pharmaceutical composition. Background technique [0002] Coronary heart disease is coronary heart disease, which mainly refers to a series of clinical symptoms resulting from the accumulation of lipid substances in the arterial intima to form atherosclerotic lesions due to abnormal lipid metabolism. With the improvement of people's living standards, changes in living habits, and the acceleration of the aging society, the incidence of coronary heart disease is increasing, and the risk factors affecting the occurrence and development of coronary heart disease are increasing, which seriously endangers human health. At present, the common drugs for the treatment of coronary heart disease mainly include anticoagulants, vasodilators, nitrates, antiplatelet aggr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/40A61K31/381A61P9/10
CPCA61K31/40A61K31/381A61P9/10A61K2300/00
Inventor 徐迎佳薛金贵黄日太
Owner THE FIFTH PEOPLES HOSPITAL OF SHANGHAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products